Evidence map›Paper›PMID 31571987›Full record

ArticleCancer management and research2019

Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods.

Hong-Mei Zhang, Xi-Yang Liu, Yu-Zhang Liu, Li-Na Liu, Quan-De Lin, Yong-Ping Song, Bai-Jun Fang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hong-Mei ZhangDepartment of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, the Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450008, People's Republic of China.
Xi-Yang LiuDepartment of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, the Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450008, People's Republic of China.
Yu-Zhang LiuDepartment of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, the Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450008, People's Republic of China.
Li-Na LiuDepartment of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, the Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450008, People's Republic of China.
Quan-De LinDepartment of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, the Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450008, People's Republic of China.
Yong-Ping SongDepartment of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, the Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450008, People's Republic of China.
Bai-Jun FangDepartment of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, the Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450008, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aims to compare the efficacy and adverse reactions of bortezomib for treating newly diagnosed multiple myeloma (MM) through two different administration methods: intravenous (IV) injection and subcutaneous (SC) injection.

methodsA retrospective analysis was performed in 205 patients with newly diagnosed MM, who were treated by the Department of Hematopathology, Henan Cancer Hospital, from June 2009 to December 2017. These patients were divided into two groups according to the treatment methods: IV injection group, IV injection of bortezomib; SC injection group, SC injection of bortezomib.

resultsAfter the first course of treatment, the effect of very good partial remission (VGPR) or above (≥VGPR) in the IV injection group (IV group) and SC injection group (SC group) was 31.0% and 14.3%, respectively (

conclusionCompared with IV administration, SC bortezomib can provide a better balance between efficacy and toxicity.

Indexed as

bortezomibintravenous injectionmultiple myelomasubcutaneous injection

Identifiers

PMID31571987
PMCPMC6749981

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.